Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Disulfiram · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Disulfiram | DRUG | - |
Please contact site for information.
Disulfiram is used for alcohol-related disorders, specifically as a treatment for alcohol dependence. It is a small molecule being developed by National Healthcare Corp. (NHC). The drug is currently in Phase 2 clinical development, though the available trial data is from a completed study.
Disulfiram works by interfering with alcohol metabolism, causing unpleasant effects when alcohol is consumed. It inhibits the enzyme acetaldehyde dehydrogenase, leading to an accumulation of acetaldehyde, which produces aversive symptoms. This mechanism is intended to discourage alcohol consumption in individuals with alcohol-related disorders.
Disulfiram is being developed by National Healthcare Corp., which trades under the ticker NHC. The company is conducting clinical research on this small molecule for the treatment of alcohol-related disorders. The drug is currently in Phase 2 development.
Disulfiram is in Phase 2 clinical development. It is an investigational drug, not yet approved by the FDA. The available trial data includes one completed Phase 2 study, and the drug is being studied for alcohol-related disorders.
Disulfiram has one completed clinical trial, NCT00000278, titled 'Disulfiram for Cocaine-Alcohol Abuse - 3'. This Phase 2 study was conducted in the United States and enrolled adults aged 18 years and older. The trial was uncontrolled and not randomized or double-blinded.
Disulfiram is the generic name for the drug also known as Antabuse. It is a small molecule used to treat alcohol-related disorders. The drug is currently in Phase 2 development by National Healthcare Corp. (NHC) for this indication.